A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-25

Study Completion Date

2025-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn about the safety of Tafamidis for the treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM) in India.

ATTR-CM is a condition that affects people's hearts. Transthyretin is a protein that is made in the liver. In some people this protein stops working and forms clumps called as amyloid. Transthyretin amyloid builds up in heart and stops the heart from pumping properly.

This study is seeking for participants who are:

* confirmed with ATTR-CM.
* given Tafamidis capsules to be taken by mouth.

The safety of Tafamidis capsules will be checked based on side effects. These side effects can happen within 6 months after taking Tafamidis. A side effect is something (expected or unexpected) that you feel was caused by a medicine or treatment you take. The study doctor will collect side effect information and put the information on patient's case form.

Follow-up of the patient's will be performed via clinic re-visit or over a call. It is not a rule for the participants to visit the clinic in this study.

This study will help to see if Tafamidis is safe.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

NCT00935012

ATTR-CM TTR-CM

COMPLETED PHASE3

Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases

NCT05329350

Muscular Ventricular Septal Defect

RECRUITING

Capstan Medical TMVR Study: FIH

NCT06600191

Mitral Regurgitation

RECRUITING NA

Transcatheter Mitral Valve Repair as Bridge Therapy to Heart Transplantation

NCT04293575

Heart Failure Mitral Regurgitation End-stage Heart Failure

UNKNOWN

Caisson Transcatheter Mitral Valve Replacement (TMVR)

NCT03661398

Mitral Regurgitation Mitral Valve Disease Mitral Valve Failure +3 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transthyretin Amyloid Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ATTR-CM in India

Tafamidis

Intervention Type DRUG

Patients on tafamidis will be observed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tafamidis

Patients on tafamidis will be observed

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (age ≥18 years) with diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
* Patients to whom VyndaMx® Capsules is prescribed for the treatment of wild or hereditary ATTR-CM.

Exclusion Criteria

* Patient with hypersensitivity to VyndaMx® Capsule or to any of the excipients in the product.
* Patients with rare hereditary problems of fructose intolerance.
* Patient who has a contraindication to VyndaMx® Capsules according to the approved local product label.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No